LBI-1026

THERAPEUTIC AREA

CANNABINOID THERAPIES

LBI-1026

Indications:
Pain, Nausea & Vomiting, Epilepsy,
Neuropathy, Glaucoma
REGULATORY PATHWAY

Improved 505(b)(2) Formulations

TARGET INDICATION

First non-toxic dosage forms of CBD & THC: IV, Inhalation, Oral & Ophthalmic

CURRENT DEVELOPMENT STATUS

Pre-clinical 55 nanometer CBD based formulation complete. New LASSN Cannabis patents filed March 2019. Development is paused until funding is secured. Non-binding Memorandum of understanding has been executed and securities council retained

NEXT DEVELOPMENT PHASE

Formulating and licensing to include THC, bioavailability, safety & efficacy animal models, San Diego development laboratory

TIME TO HUMAN BENEFIT

Recreational products within 1.5 ears and first FDA approved human trials 2 years from funding and staffing

IMMEDIATE FUNDING REQUIREMENT

Yes, please inquire